Stocks and Investing Stocks and Investing
Wed, October 19, 2022
Tue, October 18, 2022

Matt Miksic Initiated (TNDM) at Buy and Held Target at $75 on, Oct 18th, 2022


Published on 2024-10-27 23:27:09 - WOPRAI, Matt Miksic
  Print publication without navigation


Matt Miksic of Barclays, Initiated "Tandem Diabetes Care, Inc." (TNDM) at Buy and Held Target at $75 on, Oct 18th, 2022.

Matt has made no other calls on TNDM in the last 4 months.



There are 5 other peers that have a rating on TNDM. Out of the 5 peers that are also analyzing TNDM, 0 agree with Matt's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Matt


  • Matthew Taylor of "Jefferies" Initiated at Strong Buy and Held Target at $75 on, Wednesday, October 12th, 2022
  • Larry Biegelsen of "Wells Fargo" Downgraded from Buy to Sell and Decreased Target to $49 on, Tuesday, August 9th, 2022
  • Lawrence Biegelsen of "Wells Fargo" Maintained at Buy with Decreased Target to $82 on, Thursday, August 4th, 2022
  • Matt O'Brien of "Piper Sandler" Maintained at Buy with Decreased Target to $80 on, Thursday, August 4th, 2022
  • Jayson Bedford of "Raymond James" Maintained at Buy with Decreased Target to $90 on, Thursday, August 4th, 2022

Contributing Sources